

Docket No.: **515-4218**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT OPERATIONS

**RECEIVED**

DEC 1 0 2003

TECH CENTER 1600/2900

In re Application of:

**Achile Arini, et al.**

Serial No.: 09/815,533

Filed: March 16, 2001

)  
)  
) Group Art Unit: 1652  
)  
) Examiner: Steadman, David J.  
)  
)

For: **A METHOD FOR THE PRODUCTION OF PHARMACEUTICALLY ACTIVE RECOMBINANT PROTEINS**

New York, NY 10036  
December 4, 2003

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

This Information Disclosure Statement is being filed under the provisions of 37 CFR§1.97.

EPO Search Report	Lists references cited by the Examiner.
Cell Structure and Function vol. 14 no. 5, Pgs 579-586 (1989)	Disclose effect of butyrate on expression of human preprourokinase.
Biotechnology and Bioengineering Vol. 55 No.2 (1997)	Discloses use of fermentor temperature for control of high-density cultures of mammalian cells.
Journal of Biological Chemistry vol.263, no. 7 Pgs 3063-3066(1988)	Discloses secretion of soluble functional insulin receptors of NIH3T3 cells.
Proceeding of the National Academy of Sciences USA Vol.85 No. 1 Pgs 126-130 (1988)	Discloses expression of human epidermal growth factors precursor.

Proceeding of the  
National Academy of  
Sciences USA Vol.93 No. 1  
Pgs 65-70 (1996)

Discloses method of producing human lysosomal  
acid  $\alpha$ -glucosidase.

EP 0 180 859 A2

Cited by the Examiner.

DE 28 15 853 A1

Cited by the Examiner.

WO 00/65070

Discloses cell culture process.

WO 00/00624

Discloses production of urokinase.

Australian Official Action

Lists references cited by Australian Examiner.

FR 900.826

Discloses use of E. coli clone in the production of  
preprourokinase.

WO 90/04023

Discloses production of human preprourokinase.

The Journal of Biological  
Vol. 266, No.8 Pgs 5147-  
5152 (1991)

Discloses activation of prpenzyme urokinase-type  
plasminogen activator.

The Journal of Biological  
Vol. 267, No.6 Pgs 3878-  
3885 (1992)

Discloses domain structure and interactions of  
recombinant Urokinase-type plasminogen activator.

The Journal of Biological  
No.8 Pgs 17120-  
17126 (1986)

Discloses purification of a novel low molecular  
weight urokinase plasminogen activator.

Applicant petitions for consideration the attached prior art under 37  
CFR 1.97. Authorization is given to charge Deposit Account No. 08-1540 for the  
acquired fee.

Respectfully submitted,



James V. Costigan


Registration No. 25,669

HEDMAN & COSTIGAN, P.C.  
1185 Avenue of the Americas  
New York, NY 10036-2646  
(212) 302-8989


I hereby certify that this correspondence is being  
deposited with the United States Postal Service  
as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on : December 4, 2003



James V. Costigan, Registration No. 25,669



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/815,533
		Filing Date	March 16, 2001
		First Named Inventor	Achile Arini, et al
		Art Unit	1652
		Examiner Name	Steadman, David J.
Sheet 1	of 1	Attorney Docket Number	515-4218

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code 2 (if known)			
	AA	US-			
	AB	US-			
	AC	US-			
	AD	US-			
	AE	US-			
	AF	US-			
	AG	US-			
	AH	US-			
	AI	US-			
	AJ	US-			
	AK	US-			
	AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-			
	AT	US-			

RECEIVED

DEC 10 2003

TECH CENTER 1600/2900


FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code 3 - Number 4 - Kind Code 5 (if known)				
	AU	EP 0 180 859	5/14/1996	Behringwerke AG		
	AV	DE 28 15 853	10/19/1978	Choay SA		
	AW	WO 00/65070	11/2/2000	Genentech Inc.		
	AX	WO 00/00624	1/6/2000	Croptech Devl. Corp.		
	AY	FR 900.826	10/16/1934			
	AZ	WO 90/04023	4/19/1990	Farmitalia Carlo		
	BA					
	BB					
	BC					
	BD					

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	09/815,533
Sheet 2 of 2		Filing Date	March 16, 2001
		First Named Inventor	Achile Arini, et al
		Group Art Unit	1652
		Examiner Name	Steadman, David J.
		Attorney Docket Number	515-4218

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BE	EPO Search Report	
	BF	Cell Structure and Function vol. 14 no. 5, Pgs 579-586 (1989)	
	BG	Biotechnology and Bioengineering Vol. 55 No.2 Pgs 328-338 (1997)	
	BH	Journal of Biological Chemistry vol.263, no. 7 Pgs 3063-3066 (1988)	
	BI	Proceeding of the National Academy of Sciences USA Vol.85 No. 1 Pgs 126-130 (1988)	
	BJ	Proceeding of the National Academy of Sciences USA Vol. 93 No. 1 Pgs 65-70 (1996)	
	BK	Australian Official Action	
	BL	The Journal of Biological Vol. 266, No.8 Pgs 5147- 5152 (1991)	
	BM	The Journal of Biological Vol. 267, No.6 Pgs 3878- 3885 (1992)	
	BN	The Journal of Biological No.8 Pgs 17120- 17126 (1986)	
	BO		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.